Alder BioPharmaceuticals (ALDR) PT Raised to $26.00 at BMO Capital Markets

Jeannie Matthews
January 14, 2018

SG Americas Securities LLC now owns 15,580 shares of the biopharmaceutical company's stock worth $178,000 after acquiring an additional 8,140 shares in the last quarter. State Street Corp now owns 1,291,370 shares of the biopharmaceutical company's stock valued at $32,237,000 after buying an additional 95,570 shares in the last quarter. Marianas Fund Management Llc who had been investing in Starbucks Corp for a number of months, seems to be bullish on the $85.11B market cap company. This represents a decrease of -3% in the number of shares being shorted compared to the previous reading, and implies that investors felt less pessimistic about the stock during the past two weeks. Its down 6.47% from 7.45M shares, reported previously. It has underperformed by 5.29% the S&P500. Alder BioPharmaceuticals has a 52-week low of $8.60 and a 52-week high of $25.45. Artisan Partners Limited Partnership sold 194,688 shares as the company's stock rose 18.92% with the market. BB Biotech AG now owns 1,685,150 shares of the biopharmaceutical company's stock valued at $42,078,000 after buying an additional 175,000 shares in the last quarter. The stock decreased 1.14% or $0.2 during the last trading session, reaching $17.35. Finally, its 100-day average volume is 1,195,724 shares with 100% of long-term indicators pointing to Buy.

Shares of Alder BioPharmaceuticals (NASDAQ:ALDR) traded down $0.45 during midday trading on Friday, reaching $12.95. It has underperformed by 50.37% the S&P500.

Senzar Asset Management Llc, which manages about $442.00 million and $409.74M US Long portfolio, decreased its stake in Halozyme Therapeutics Inc (NASDAQ:HALO) by 257,074 shares to 3.83M shares, valued at $66.53M in 2017Q3, according to the filing. Therefore 27% are positive. Cognex Corporation had 35 analyst reports since August 4, 2015 according to SRatingsIntel. The firm has "Buy" rating by Daiwa Securities given on Friday, December 8. The firm has "Buy" rating by Standpoint Research given on Monday, July 27. On Friday, October 30 the stock rating was maintained by UBS with "Buy". The stock has "Mkt Perform" rating by FBR Capital on Wednesday, November 11. Citigroup downgraded the stock to "Neutral" rating in Friday, August 5 report.

Alder Biopharmaceuticals Inc. (ALDR) analysts on average have given a price target of $24 on ALDR stock. BMO Capital Markets restated a buy rating and set a $22.00 target price on shares of Alder BioPharmaceuticals in a research report on Wednesday, January 3rd.

Since September 7, 2017, it had 0 buys, and 2 selling transactions for $4.70 million activity. The stock was sold at an average price of $22.78, for a total value of $82,828.08.

QUANTRES ASSET MANAGEMENT Ltd Purchases New Holdings in Electronic Arts Inc. (EA)
The firm has "Overweight" rating by Barclays Capital given on Friday, February 12. 871 were reported by Alpha Windward Limited. Sumitomo Mitsui Asset Management Company LTD increased its stake in shares of Electronic Arts by 1.4% in the second quarter.

Texans extend head coach Bill O'Brien's contract
There was speculation about O'Brien's future with the Texans after the team went 4-12 this season. Get prep sports breaking news alerts from the Gwinnett Daily Post staff delivered to your email.

ISPR DG terms India's army chief 'nuclear bluff' statement deplorable
Pakistan is at it again with Pakistan Foreign Minister Khawaja Muhammad Asif making a scathing tweet hinting at a nuclear attack on India.

Investors sentiment increased to 1.24 in 2017 Q3. Its down 0.28, from 1.33 in 2017Q2. It dropped, as 95 investors sold SBUX shares while 448 reduced holdings. 43 funds opened positions while 81 raised stakes. (NASDAQ:FEYE) or 1,200 shares. Following the transaction, the chief executive officer now owns 124,768 shares in the company, valued at $3,139,162.88. Advisory Ser Net Limited Liability invested in 2,030 shares. National Bank & Trust Of Ny Mellon holds 745,667 shares or 0% of its portfolio. Cambridge Inv Advisors holds 33,330 shares or 0.01% of its portfolio. Sandy Spring Savings Bank owns 230 shares for 0% of their portfolio. ValuEngine raised shares of Alder BioPharmaceuticals from a "strong sell" rating to a "sell" rating in a research report on Saturday, September 30th. Therefore 88% are positive. Zacks Investment Research lowered shares of Alder BioPharmaceuticals from a "hold" rating to a "sell" rating in a report on Thursday. Alder Biopharmaceuticals, Inc. (ALDR) has made its way to a 12-month decline of -12.9%. The company now has a consensus rating of "Buy" and a consensus price target of $40.67. The rating was maintained by BMO Capital Markets on Wednesday, August 9 with "Outperform". Barclays Capital maintained the stock with "Equal Weight" rating in Tuesday, January 31 report. The firm earned "Outperform" rating on Tuesday, March 29 by Credit Suisse. The stock has "Overweight" rating by Piper Jaffray on Monday, October 31. Wall Street is only getting more bullish on the stock, with 10 of analysts who cover ALDR having a buy-equivalent rating.

Alder Biopharmaceuticals, Inc is a clinical-stage biopharmaceutical company. Jefferies has "Buy" rating and $62 target.

Analysts await Teva Pharmaceutical Industries Limited (NYSE:TEVA) to report earnings on February, 12. (NASDAQ:ALDR) rating on Thursday, August 24. They expect $0.25 EPS, up 13.64% or $0.03 from last year's $0.22 per share.

Alder BioPharmaceuticals (NASDAQ:ALDR) last posted its quarterly earnings results on Tuesday, November 7th.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Other reports by

Discuss This Article

FOLLOW OUR NEWSPAPER